LIPOSYN III 20% Drug Patent Profile
✉ Email this page to a colleague
When do Liposyn Iii 20% patents expire, and what generic alternatives are available?
Liposyn Iii 20% is a drug marketed by Hospira and is included in one NDA.
The generic ingredient in LIPOSYN III 20% is soybean oil. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the soybean oil profile page.
Summary for LIPOSYN III 20%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 4 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | LIPOSYN III 20% at DailyMed |
Recent Clinical Trials for LIPOSYN III 20%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The Cleveland Clinic | Early Phase 1 |
| Pennington Biomedical Research Center | Early Phase 1 |
| The University of Texas Health Science Center at San Antonio | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for LIPOSYN III 20%
US Patents and Regulatory Information for LIPOSYN III 20%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | LIPOSYN III 20% | soybean oil | INJECTABLE;INJECTION | 018970-001 | Sep 25, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
